Lexicon Pharmaceuticals 향후 성장

Future 기준 점검 1/6

Lexicon Pharmaceuticals (는) 각각 연간 15.4% 및 14.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -33.9% 로 예상됩니다.

핵심 정보

15.4%

이익 성장률

21.42%

EPS 성장률

Pharmaceuticals 이익 성장	12.9%
매출 성장률	14.5%
향후 자기자본이익률	-33.94%
애널리스트 커버리지	Low
마지막 업데이트	10 Dec 2025

최근 향후 성장 업데이트

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

May 17

Recent updates

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Dec 18

Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well

Dec 03

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%

Oct 02

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump

Jul 28

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%

Jun 13

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts

May 19

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

May 17

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options

Apr 01 Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)

Mar 28

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Mar 26

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Oct 16

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

이익 및 매출 성장 예측

NasdaqCM:LXRX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	61	-74	N/A	N/A	3
12/31/2027	18	-107	N/A	N/A	4
12/31/2026	15	-107	N/A	N/A	5
12/31/2025	47	-63	N/A	N/A	5
9/30/2025	71	-69	-73	-72	N/A
6/30/2025	58	-121	-103	-102	N/A
3/31/2025	31	-177	-168	-167	N/A
12/31/2024	31	-200	-180	-179	N/A
9/30/2024	5	-216	-208	-208	N/A
6/30/2024	4	-202	-196	-196	N/A
3/31/2024	2	-194	-186	-185	N/A
12/31/2023	1	-177	-162	-162	N/A
9/30/2023	1	-158	-135	-133	N/A
6/30/2023	0	-131	-112	-111	N/A
3/31/2023	0	-110	-99	-97	N/A
12/31/2022	0	-102	-90	-89	N/A
9/30/2022	0	-97	-90	-90	N/A
6/30/2022	0	-97	-88	-88	N/A
3/31/2022	0	-90	-87	-85	N/A
12/31/2021	0	-88	-88	-87	N/A
9/30/2021	0	-68	-100	-98	N/A
6/30/2021	7	38	38	-122	N/A
3/31/2021	16	-13	14	-146	N/A
12/31/2020	24	-59	17	-143	N/A
9/30/2020	33	-104	27	-133	N/A
6/30/2020	320	39	98	98	N/A
3/31/2020	321	85	117	117	N/A
12/31/2019	322	130	114	114	N/A
9/30/2019	330	164	111	111	N/A
6/30/2019	43	-89	N/A	-102	N/A
3/31/2019	47	-101	N/A	-127	N/A
12/31/2018	63	-121	N/A	-149	N/A
9/30/2018	81	-126	N/A	-155	N/A
6/30/2018	101	-129	N/A	-167	N/A
3/31/2018	99	-130	N/A	-147	N/A
12/31/2017	92	-123	N/A	-185	N/A
9/30/2017	80	-133	N/A	-200	N/A
6/30/2017	81	-138	N/A	-202	N/A
3/31/2017	89	-141	N/A	-217	N/A
12/31/2016	79	-131	N/A	-176	N/A
9/30/2016	188	-22	N/A	139	N/A
6/30/2016	160	-22	N/A	149	N/A
3/31/2016	141	-11	N/A	165	N/A
12/31/2015	130	-5	N/A	185	N/A
9/30/2015	24	-94	N/A	-86	N/A
6/30/2015	24	-100	N/A	-81	N/A
3/31/2015	24	-98	N/A	-69	N/A

애널리스트 향후 성장 전망

수입 대 저축률: LXRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: LXRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: LXRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: LXRX 의 수익(연간 14.5%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: LXRX 의 수익(연간 14.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: LXRX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/04 22:33
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Lexicon Pharmaceuticals, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Yigal Nochomovitz	Citigroup Inc
Joseph Pantginis	H.C. Wainwright & Co.
Andrew Tsai	Jefferies LLC

Lexicon Pharmaceuticals 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 17% to US$3.05

Consensus revenue estimates increase by 48%

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

Price target decreased by 13% to US$4.68

Consensus revenue estimates decrease by 24%

Price target increased by 16% to US$6.25

Recent updates

New major risk - Revenue and earnings growth

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals, Inc. Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Ayl-Coa Synthetase 5 (Acsl5) Reinforcing the Scientific Rationale for Lx9851

Lexicon Pharmaceuticals, Inc. Announces Clinical Data on Adipose Distribution in Non-Diabetic Patients to Be Presented At the 2025 Cardio Vascular Clinical Trialists Forum

Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well

New major risk - Revenue and earnings growth

Lexicon Pharmaceuticals, Inc. Announces Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure Without Diabetes Presented At American Heart Association Annual Scientific Sessions 2025

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Lexicon Pharmaceuticals, Inc. Announces Data from Three Studies of Sotagliflozin to Be Presented At the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Lexicon Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Lexicon Pharmaceuticals, Inc. Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%

Lexicon Pharmaceuticals, Inc. Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista®? in Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. Announces the Presentation of Clinical Data from the Company's Phase 2B Progress Study for Its Investigational, AAK1-Inhibitor, Pilavapadin, for the Treatment of Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista®? in Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. Presents Post-Hoc Analysis of Sotagliflozin Among Older Adults

Second quarter 2025 earnings released

Price target increased by 17% to US$3.05

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump

Lexicon Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Clinical Study Data Showing A Reduction in Hypoglycemia Events When Added to Optimized Insulin

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%

Consensus revenue estimates increase by 48%

Lexicon Pharmaceuticals, Inc. Announces Details of Its "Sotagliflozin" in Patients with Symptomatic Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy (Hcm) Study

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 13, 2025

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Lexicon Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 06, 2025

Lexicon Pharmaceuticals, Inc. Publishes Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events

New major risk - Shareholder dilution

Lexicon Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Lexicon Pharmaceuticals, Inc. Announces CFO Changes

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Price target decreased by 13% to US$4.68

Lexicon Pharmaceuticals, Inc. Announces Board Changes

Consensus revenue estimates decrease by 24%

New major risk - Financial position

Price target increased by 16% to US$6.25

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Price target decreased by 16% to US$5.40

Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Consensus revenue estimates increase by 33%

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces Management Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much